19064-64-3

Usage

Uses

Used in Pharmaceutical Industry:
3,6-Dichloro-4-methylpyridazine is used as a synthetic intermediate for the production of 7-methyl-2-phenylimidazo[1,2-b]pyridazine-3-carboxylic acid, which has potential applications in the development of pharmaceuticals.
Used in Chemical Synthesis:
3,6-Dichloro-4-methylpyridazine is used as a building block in the synthesis of various organic compounds, particularly those with potential applications in the pharmaceutical, agrochemical, and material science industries. Its unique structure allows for further functionalization and modification to create a wide range of products.

InChI:InChI=1/C5H4Cl2N2/c1-3-2-4(6)8-9-5(3)7/h2H,1H3

Upstream product

• 5754-18-7 4-methyl-1,2-dihydropyridazine-3,6-dione 
• 117122-49-3 methyl-maleic acid dihydrazide 
• 616-02-4 citraconic acid anhydride 
• 5754-18-7 3,6-dihydroxy-4-methylpyridazine 

Downstream Products

• 89466-36-4 3-chloro-6-methoxy-4-methylpyridazine 
• 89466-38-6 6-chloro-3-methoxy-4-methylpyridazine 
• 89943-29-3 4-Methyl-3,6-dimethoxy-pyridazin 
• 1120-88-3 4-methylpyridazine 
• 1834-27-1 6-chloro-4-methyl-2H-pyridazin-3-one 
• 1703-07-7 6-chloro-5-methyl-2H-pyridazin-3-one 
• 66346-87-0 6-chloro-5-methylpyridazin-3-amine 
• 64068-00-4 3-amino-6-chloro-4-methylpyridazine 
• 66530-56-1 (6-chloro-5-methylpyridazin-3-yl)hydrazine 
• 66530-55-0 6-chloro-3-hydrazino-4-methylpyridazine 
• 50681-26-0 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylic acid 
• 6531-08-4 3,6-dichloropyridazine-5-carboxylic acid chloride 
• 54709-94-3 5-methylpyridazin-3(2H)-one 
• 58826-39-4 6-chloro-7-methyl[1,2,4]triazolo[4,3-b]pyridazine 

Relevant academic research and scientific papers

THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF

Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.

PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON

The present invention relates to the treatment of oncological, chronic inflammatory and similar diseases with the aid of new families of chemical compounds having improved efficiency with regard to the inhibition of Abl kinase and mutant forms thereof, as well as other therapeutically significant kinases. It describes protein kinase inhibitors in the form of compounds of general formula (I) and compounds of general formula (II), or a tautomer, an individual isomer, a mixture of isomers, a pharmaceutically acceptable salt, a solvate or a hydrate thereof.

Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors

Searching for selective tankyrases (TNKSs) inhibitors, a new small series of 6,8-disubstituted triazolo[4,3-b]piridazines has been synthesized and characterized biologically. Structure-based optimization of the starting hit compound NNL (3) prompted us to the discovery of 4-(2-(6-methyl-[1,2,4] triazolo[4,3-b]pyridazin-8-ylamino)ethyl)phenol (12), a low nanomolar selective TNKSs inhibitor working as NAD isostere as ascertained by crystallographic analysis. Preliminary biological data candidate this new class of derivatives as a powerful pharmacological tools in the unraveling of TNKS implications in physiopathological conditions.

Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity

(-)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4, 5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity. A survey of potential bicyclic heteroaromatic replacement subunits for the pyrazolo[1,5-a]pyridine core of KCA-1490 has identified the 4-methoxy-2- (trifluoromethyl)benzo[d]thiazol-7-yl and 8-methoxy-2-(trifluoromethyl)quinolin- 5-yl analogues as dual PDE3/4-inhibitory compounds that potently suppress histamine-induced bronchoconstriction and exhibit anti-inflammatory activity in vivo.

Preparation of substituted pyridazines

A novel process is described for preparing substituted pyridazines, where a less substituted pyridazine is reacted with a carboxylic acid in the presence of a silver ion as catalyst, using peroxydisulfate ion. The reaction is run at a temperature from about 40° to 80° C. in an aqueous solvent system and mineral acid. The substituted pyridazines are useful as intermediates to herbicidal and fungicidal compounds.

6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds

8-Methyl-1,2,4-triazolo[4,3-b]pyridazines having a hydroxyalkylamino substituent at the 6-position are described herein. The compounds involved are useful as bronchodilator agents and they are prepared by the reaction of 6-chloro-8-methyl-1,2,4-triazolo[4,3-b]-pyridazine with an appropriate amino alcohol.